False extended-spectrum β-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 301-308

  Beceiro, A ^a   Fernandez cuenca F ^b   Ribera, A ^c   Martinez martinez L ^b,e   Pascual, A ^b   Vila, J ^c   Rodriguez bano J ^b   Cisneros, J M ^d   Pachon J ^d   Bou, German ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

lactamase inhibitors; Disc diffusion; PBP alterations

Indexed keywords

BETA LACTAMASE AMPC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN; SULBACTAM;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIFFUSION; DILUTION; DRUG POTENTIATION; ENZYME SYNTHESIS; FALSE POSITIVE RESULT; GENETIC VARIABILITY; GENOTYPE; ISOELECTRIC FOCUSING; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; STRAIN DIFFERENCE;

ACINETOBACTER; BETA-LACTAMASES; CLAVULANIC ACID; DRUG RESISTANCE, BACTERIAL; FALSE POSITIVE REACTIONS; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 38349125651     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm461     Document Type: Article

References (36)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Micrabiol Rev 1996; 9: 148-65.
2. Levi I, Rubinstein E. Acinetobacter infections-overview of clinical features. In: Bergogne-Berazin E, Joly-Guillou ML, Towner KJ, eds. Acinetobacter: Microbiology, Epidemiology, Infections, Management. New York, NY: CRC Press, 1996; 101-15.
3. Amyes SGB, Young H-K. Mechanism of antibiotic resistance in Acinetobacter spp. - genetics of resistance. In: Bergogne-Berezin E, Joly-Guillou ML, Towner KJ, eds. Acinetobacter: Microbiology, Epidemiology, Infections, Management. New York, NY: CRC Press, 1996; 185-223.
4. Beceiro A, Domínguez L, Ribera A et al. Molecular characterization of the gene encoding a now AmpC β-lactamase in a clinical strain of Acinetobacter genomic species 3. Antimicrob Agents Chemother 2004; 48: 1374-8.
5. Bergogne-Bérézin E. Resistance of Acinetobacter spp. to antimicrobials - overview of clinical resistance patterns and therapeutic problems. In: Bergogne-Berezin E, Joly-Guillou ML, Towner KJ, eds. Acinetobacter: Microbiology, Epidemiology, Infections, Management. New York, NY: CRC Press, 1996; 133-83.
6. Bou G, Cervero G, Domínguez MA et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000; 38: 3299-305.
7. Bou G, Martínez-Beltran J. Cloning, nucleotide sequencing, and analysis of the gene encoding an AmC β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2000; 44: 428-32.
8. Donald HM, Scaife W, Amyes SGB et al. Sequence analysis of ARI-1, a novel OXA β-lactamase responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000; 44: 196-9.
9. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC et al. Relationship between β-lactamase production, outer membrane protein, and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003; 51: 565-74.
10. Henwood CJ, Gaiward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
11. Van Looveren M, Goossens H, the ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2604; 10: 684-704.
12. Vila J, Marcos MA, Marco F et al. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37: 138-41.
13. Rodriguez-Hernandez MJ, Cuberos L, Pichardo C et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother 2001; 47: 479-82.
14. Suh B, Shapiro T, Jones R et al. In vitro activity of β-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995; 2: 111-4.
15. Montero A, Ariza J, Corbella X et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002;.46: 1946-52.
16. Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45: 583-8.
17. Nordmann P, Poirel L. Emerging carbapenomases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-31.
18. Poirel L, Menuteau O, Agoli N et al. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003, 41: 3542-7.
19. Walsh TR, Toleman MA, Poirel L et al. Metallo-β-lactamases: The quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
20. Clark RB. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa. outer membrane protein. J Antimicrob Chemother 1996; 38: 245-51.
21. Gehrlein M, Laying H, Cullmann W et al. Imipenern resistance in Acinetobacter baumannii is due to altered penicillin-binding proteins. Chemotherapy 1991; 37: 405-12.
22. Limansky AS, Mussi MA, Viale AM. Loss of a 29-kDa outer membrane protein in Acinetebacter baumannii is associated with imipenem resistance. J Clin Microbiol 2002; 40: 4776-8.
23. Tomas, M, Beceiro A, Perez A et al. Cloning and functional analysis of the gone encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005; 49: 5172-5.
24. Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disc diffusion methods. J Clin Microbiol 2004; 42: 5102-8.
25. Fernández-Cuenca F, Pascual A, Ribera A et al. Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project 2000. Enferm Intecc Microbiol Clin 2004; 22: 267-71.
26. Vaneechoutte M, Disjkshoom L, Tjemberg I et al. Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis. J Clin Microbiol 1995; 33: 11-5.
27. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
28. Livermore DM, Brown DFJ. Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48 SuppI S1: 59-64.
29. Carter MW, Oakton KJ, Warner M et al. Detection of extended-spectrum β-lactamases in Klebsiollae with the Oxoid combination disk method. J Clin Microbiol 2000; 38: 4228-32.
30. Gautom RK. Rapid pullsed-fleld gel electrophoresis protocol for typing of Escherichia coli 0 157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 1997; 35: 2977-80.
31. Bou G, Cerveró G, Domínguez MA et al. PCR-based DNA fingerprinting (REP-PCR, AP-PCR) and pulsed-field gel electrophoresis characterization of a nosocomial outbreak caused by imipenem- and meropenem-resistant Acinetobacter baumannii. Clin Microb Infect 2000; 6: 635-43.
32. Matthew M, Harris AM, Marshall M et al. The use of analytical isoelectric focusing for detection and identification of β-lactamases. J Gen Microbiol 1975; 88: 169-78.
33. Corbella X, Montero A, Pujol M et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000; 38: 4086-95.
34. Pandey A, Kapil A, Sood S et al. In vitro activities of ampicillin-sulbactam and amoxicillin-clavulanic acid against Acinetobacter baumannii. J Clin Microbol 1998; 36: 3415-6.
35. Sturenburg E, Lang M, Horstkotte MA et al. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum β-lactamases in clinical isolates of oxyimino-caphalosporin-resistant Gram-negative bacteria. J Antimicrob Chemother 2004; 54:870-5.
36. Higgins PG, Wisplinghoff H, Stefanik D et al. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004; 48: 1586-92.